Premium
mRNA Delivery System for Targeting Antigen‐Presenting Cells In Vivo
Author(s) -
Fornaguera Cristina,
GuerraRebollo Marta,
Ángel Lázaro Miguel,
CastellsSala Cristina,
MecaCortés Oscar,
RamosPérez Victor,
Cascante Anna,
Rubio Núria,
Blanco Jerónimo,
Borrós Salvador
Publication year - 2018
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201800335
Subject(s) - in vivo , immunotherapy , transfection , immune system , oligopeptide , messenger rna , context (archaeology) , gene delivery , cancer immunotherapy , systemic administration , biology , immunology , cancer research , medicine , gene , peptide , biochemistry , paleontology , microbiology and biotechnology
Abstract The encapsulation of mRNA in nanosystems as gene vaccines for immunotherapy purposes has experienced an exponential increase in recent years. Despite the many advantages envisaged within these approaches, their application in clinical treatments is still limited due to safety issues. These issues can be attributed, in part, to liver accumulation of most of the designed nanosystems and to the inability to transfect immune cells after an intravenous administration. In this context, this study takes advantage of the known versatile properties of the oligopeptide end‐modified poly (β‐amino esters) (OM‐PBAEs) to complex mRNA and form discrete nanoparticles. Importantly, it is demonstrated that the selection of the appropriate end‐oligopeptide modifications enables the specific targeting and major transfection of antigen‐presenting cells (APC) in vivo, after intravenous administration, thus enabling their use for immunotherapy strategies. Therefore, with this study, it can be confirmed that OM‐PBAE are appropriate systems for the design of mRNA‐based immunotherapy approaches aimed to in vivo transfect APCs and trigger immune responses to fight either tumors or infectious diseases.